265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort

by Luc Dirix, Frank Beier, Alain Ravaud, Theodore Gourdin, Jean-Laurent Deville, Marco Maruzzo, XiaoZhe Wang, Yulia Vugmeyster, Jeorg Seebeck, Sarah Chennoufi
Published 2020-11-01